- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Respiratory Syncytial Virus Vaccine – March 2026
Powder and suspension for injection (0.5 mL)
Last updated
11 March 2026